Press Releases August 27, 2026 09:01 AM

GRI Bio Featured in "Why Now" On-Demand Video Webcast

GRI Bio featured in 'Why Now' on-demand video webcast to highlight its innovative therapies.

By Marcus Reed GRI

GRI Bio, a biotechnology company listed on NASDAQ, announced its feature in the 'Why Now' on-demand video webcast, showcasing its work on developing therapies for inflammatory, fibrotic, and autoimmune diseases.

GRI Bio Featured in "Why Now" On-Demand Video Webcast

GRI

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

GRI Bio is highlighted in a webcast focused on innovative biotechnology developments.
The company is advancing therapies targeting inflammatory, fibrotic, and autoimmune disorders.
The webcast aims to increase awareness and visibility of GRI Bio's therapeutic pipeline.

Video webcast now available here

LA JOLLA, CA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that it is featured in a

Risks

Market and clinical development risks inherent in biotechnology and pharmaceutical industries.
Uncertainty over how much the webcast exposure will translate into investor interest or new partnerships.
The competitive landscape for therapies in inflammatory and autoimmune diseases is intense and evolving.

Menu

GRI Bio Featured in "Why Now" On-Demand Video Webcast

Key Points

Risks

More from Press Releases